{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:16:06Z","timestamp":1788002166628,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,29]]},"DOI":"10.7759\/cureus.115391","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:22:09Z","timestamp":1787998929000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Treatment Courses of Exceptional Long-Term Survivors After Multimodal Therapy Including Proton Beam Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Retrospective Case Series"],"prefix":"10.7759","author":[{"given":"Haruko","family":"Numajiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Niitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Sumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2322648","article-title":"Next-generation therapies for pancreatic cancer","volume":"18","author":"Buckley CW","year":"2024","unstructured":"Buckley CW, O'Reilly EM. Next-generation therapies for pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2024, 18:55-72. 10.1080\/17474124.2024.2322648","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi JD","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020, 395:2008-20. 10.1016\/S0140-6736(20)30974-0","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel O","year":"2019","unstructured":"Strobel O, Neoptolemos J, J\u00e4ger D, B\u00fcchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019, 16:11-26. 10.1038\/s41571-018-0112-1","journal-title":"Nat Rev Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy T","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364:1817-25. 10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff DD","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al.. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013, 369:1691-703. 10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients","volume":"264","author":"Hackert T","year":"2016","unstructured":"Hackert T, Sachsenmaier M, Hinz U, et al.. Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann Surg. 2016, 264:457-63. 10.1097\/SLA.0000000000001850","journal-title":"Ann Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12295","article-title":"Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma","volume":"4","author":"Satoi S","year":"2020","unstructured":"Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020, 4:6-13. 10.1002\/ags3.12295","journal-title":"Ann Gastroenterol Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1756891","article-title":"Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study","volume":"16","author":"Aljubran AH","year":"2026","unstructured":"Aljubran AH, Alata MK, Badran AA, et al.. Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study. Front Oncol. 2026, 16:1756891. 10.3389\/fonc.2026.1756891","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.03.07","article-title":"Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma","volume":"9","author":"Blakaj A","year":"2018","unstructured":"Blakaj A, Stein SM, Khan SA, Johung KL. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018, 9:1027-36. 10.21037\/jgo.2018.03.07","journal-title":"J Gastrointest Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta M","year":"2019","unstructured":"Palta M, Godfrey D, Goodman KA, et al.. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019, 9:322-32. 10.1016\/j.prro.2019.06.016","journal-title":"Pract Radiat Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.03.02","article-title":"Proton beam radiotherapy for pancreas cancer","volume":"11","author":"Rutenberg MS","year":"2020","unstructured":"Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol. 2020, 11:166-75. 10.21037\/jgo.2019.03.02","journal-title":"J Gastrointest Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.12.029","article-title":"A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis","volume":"103","author":"Terashima K","year":"2012","unstructured":"Terashima K, Demizu Y, Hashimoto N, et al.. A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012, 103:25-31. 10.1016\/j.radonc.2011.12.029","journal-title":"Radiother Oncol"},{"key":"ref13","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma (version 2.2026, April 22, 2026). (2026). Accessed: August 27, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1455."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.03.012","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima Y","year":"2019","unstructured":"Hiroshima Y, Fukumitsu N, Saito T, et al.. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2019, 136:37-43. 10.1016\/j.radonc.2019.03.012","journal-title":"Radiother Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02777","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"41","author":"Burris HA 3rd","year":"2023","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, et al.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 2023, 41:5482-92. 10.1200\/JCO.22.02777","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno H","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, et al.. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013, 31:1640-8. 10.1200\/JCO.2012.43.3680","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip PA","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, et al.. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020, 5:285-94. 10.1016\/S2468-1253(19)30327-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). Accessed: August 27, 2026:  https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable\u00a0and borderline resectable pancreatic cancer: A\u00a0meta-analysis of randomised controlled trials","volume":"160","author":"van Dam JL","year":"2022","unstructured":"van Dam JL, Janssen QP, Besselink MG, et al.. Neoadjuvant therapy or upfront surgery for resectable\u00a0and borderline resectable pancreatic cancer: A\u00a0meta-analysis of randomised controlled trials. Eur J Cancer. 2022, 160:140-9. 10.1016\/j.ejca.2021.10.023","journal-title":"Eur J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03992-y","article-title":"Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancer","volume":"23","author":"Shimomura O","year":"2025","unstructured":"Shimomura O, Numajiri H, Hashimoto S, et al.. Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancer. World J Surg Oncol. 2025, 23:352. 10.1186\/s12957-025-03992-y","journal-title":"World J Surg Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/bjr\/tqae217","article-title":"An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment","volume":"98","author":"Corallo C","year":"2025","unstructured":"Corallo C, Al-Adhami AS, Jamieson N, Valle J, Radhakrishna G, Moir J, Albazaz R. An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. Br J Radiol. 2025, 98:13-26. 10.1093\/bjr\/tqae217","journal-title":"Br J Radiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2026.0341","article-title":"Updates on imaging assessment of pancreatic cancer for determining anatomic and biologic resectability","volume":"27","author":"Lee SS","year":"2026","unstructured":"Lee SS, Kim DW, Lee W, Kim KP. Updates on imaging assessment of pancreatic cancer for determining anatomic and biologic resectability. Korean J Radiol. 2026, 27:634-51. 10.3348\/kjr.2026.0341","journal-title":"Korean J Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521082-clinical-characteristics-and-treatment-courses-of-exceptional-long-term-survivors-after-multimodal-therapy-including-proton-beam-therapy-for-borderline-resectable-and-locally-advanced-pancreatic-cancer-a-retrospective-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:22:10Z","timestamp":1787998930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521082-clinical-characteristics-and-treatment-courses-of-exceptional-long-term-survivors-after-multimodal-therapy-including-proton-beam-therapy-for-borderline-resectable-and-locally-advanced-pancreatic-cancer-a-retrospective-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.115391","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}